Skip to main
KOD

KOD Stock Forecast & Price Target

KOD Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 43%
Buy 29%
Hold 29%
Sell 0%
Strong Sell 0%

Bulls say

Kodiak Sciences Inc has demonstrated robust clinical efficacy through its product candidates, particularly KSI-101, which has shown significant vision gains in patients with over 90% achieving retinal dryness by Week 8. Additionally, positive data from the GLOW2 study for tarcocimab tedromer indicates a substantial increase in the probability of success (POS) in treating diabetic retinopathy (from 35% to 70%) and wet AMD (from 35% to 60%), highlighting the potential for effective therapeutic solutions in high-prevalence retinal diseases. Furthermore, the ongoing favorable reception from key opinion leaders regarding novel retinal therapies along with the solid execution of pivotal trials are factors contributing to an overall positive outlook on the company's future performance.

Bears say

Kodiak Sciences Inc. has faced significant challenges with its developmental candidates, notably the failures of the Phase 3 GLEAM and GLIMMER trials in diabetic macular edema (DME), and the Phase 2b/3 DAZZLE trial in wet age-related macular degeneration (AMD), which hinder the company's credibility and potential market position. The company faces risks related to failing to meet peak commercial revenue estimates, exacerbated by uncertainties in market size, penetration rates, and pricing strategies for its products, particularly Tarcocimab tedromer. Additionally, there are concerns regarding Kodiak Sciences's ability to secure adequate capital resources to fund ongoing operations and the development of its therapeutic pipeline, which further compounds the negative outlook on its financial stability and growth prospects.

KOD has been analyzed by 7 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 29% recommend Buy, 29% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Kodiak Sciences Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Kodiak Sciences Inc (KOD) Forecast

Analysts have given KOD a Buy based on their latest research and market trends.

According to 7 analysts, KOD has a Buy consensus rating as of Apr 9, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $35.43, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $35.43, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Kodiak Sciences Inc (KOD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.